Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADJUBIL
2024-511847-24-00Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Sep 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in biliary cancer, intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma (HC) and 2 more comparing durvalumab + tremelimumab + capecitabine with durvalumab + tremelimumab (2 arms). Primary endpoint: Recurrence free survival at 12 months. Started Sep 2024; status: completed.
02
Drugs
durvalumabtremelimumabcapecitabine
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)hilar cholangiocarcinoma (HC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on 2024-511847-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511847-24-00.